Recent Price Movement and Market Context
On 29 Dec 2025, Epigral Ltd’s share price declined by 1.18%, underperforming its sector by 1.4%. This marks the third consecutive day of losses, with the stock falling by 5.43% over this period. The current price of Rs.1263.1 is notably below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling persistent bearish momentum.
In contrast, the broader market index, Sensex, opened flat but traded slightly negative at 84,918.54 points, down 0.14% from the previous close. The Sensex remains near its 52-week high of 86,159.02, trading 1.46% below that peak and maintaining a bullish stance above its 50-day and 200-day moving averages. This divergence highlights the relative weakness in Epigral’s stock compared to the overall market.
Long-Term and Recent Performance Metrics
Over the past year, Epigral Ltd’s stock has delivered a negative return of 32.65%, significantly lagging the Sensex’s positive 7.87% gain. The stock’s 52-week high was Rs.2114.3, indicating a substantial decline of nearly 40% from that peak. This underperformance extends beyond the last year, with the stock also trailing the BSE500 index over the last three years, one year, and three months.
Financially, the company’s operating profit has contracted at an annualised rate of 5.49% over the past five years, reflecting subdued growth in core earnings. The September 2025 quarterly results further underscore this trend, with Profit Before Tax (PBT) excluding other income falling 45.2% to Rs.67.91 crores compared to the previous four-quarter average. Similarly, Profit After Tax (PAT) declined 52.6% to Rs.51.22 crores over the same period.
Interest expenses have increased notably, with a 37.3% rise to Rs.56.98 crores over the nine months ending September 2025, adding pressure on net profitability. These factors contribute to the stock’s current rating of “Sell” with a Mojo Score of 31.0, an improvement from a previous “Strong Sell” grade as of 26 Dec 2025, reflecting some stabilisation but continued caution.
This week's disclosed pick, a Large Cap from NBFC, comes with precise Target Price and analysis. Check if you're positioned right for this opportunity!
- - Precise target price set
- - Weekly selection live
- - Position check opportunity
Valuation and Efficiency Indicators
Despite the recent price weakness, Epigral Ltd exhibits some positive financial characteristics. The company maintains a high Return on Capital Employed (ROCE) of 23.19%, indicating efficient use of capital in generating earnings. Additionally, its debt servicing capability remains strong, with a low Debt to EBITDA ratio of 1.34 times, suggesting manageable leverage levels.
Valuation metrics also present an interesting picture. The company’s ROCE of 19.3% aligns with a very attractive Enterprise Value to Capital Employed ratio of 2.3, positioning the stock at a discount relative to its peers’ historical valuations. Over the past year, while the stock price has declined by 32.8%, the company’s profits have increased by 37.1%, resulting in a PEG ratio of 0.4, which typically signals undervaluation when considered alongside growth.
Promoters remain the majority shareholders, maintaining significant control over the company’s strategic direction.
Holding Epigral Ltd from Specialty Chemicals? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Key Concerns
The stock’s decline to Rs.1263.1 reflects a combination of factors including sustained negative returns over the past year, underwhelming profit growth, and increased interest expenses. The quarterly results from September 2025 highlight a sharp contraction in profitability, which has weighed on investor sentiment and contributed to the stock’s underperformance relative to the Sensex and its sector peers.
Trading below all major moving averages further emphasises the current bearish trend, while the stock’s Mojo Grade of “Sell” and a low Market Cap Grade of 3 underline the cautious stance adopted by market analysts. The company’s long-term growth rate in operating profit remains negative, which has been a persistent drag on valuation and price momentum.
Market and Sector Comparison
While Epigral Ltd has faced headwinds, the broader Specialty Chemicals sector and the Sensex index have shown relative resilience. The Sensex’s proximity to its 52-week high and its position above key moving averages contrast with Epigral’s weakening technical indicators. This divergence suggests that the stock’s challenges are more company-specific rather than reflective of sector-wide or market-wide trends.
Investors analysing the stock’s performance should note the disparity between the company’s operational efficiency and its market valuation, which currently trades at a discount to peers. This gap is partly attributable to recent earnings volatility and the elevated interest burden.
Conclusion
Epigral Ltd’s fall to a 52-week low of Rs.1263.1 marks a significant milestone in its recent price trajectory, underscoring ongoing pressures on profitability and valuation. The stock’s underperformance relative to the Sensex and its sector peers, combined with subdued earnings growth and rising interest costs, have contributed to this decline. However, the company’s strong capital efficiency and manageable debt levels remain notable features amid the current market environment.
As of 29 Dec 2025, the stock’s Mojo Score stands at 31.0 with a “Sell” grade, reflecting a cautious outlook based on recent financial and market data.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Saving Now →
